Merck's cardiovascular drug vorapaxar study was halted.
In mid-January, a combined Data Safety and Monitoring Board (DSMB) halted one of two Phase III trials of Merck's investigational anti-clotting drug vorapaxar because of increased risk of bleeding—specifically intracranial hemorrhage—in subjects with a history of stroke.
The TRACER study was being conducted by Duke Clinical Research Institute. It was fully enrolled in June 2010 and included 13,000 subjects with non-ST-segment-elevation acute coronary syndrome. TRA-2P, or TIMI 50 as the trial was also known, was fully enrolled in November 2009 and included 26,500 subjects who had previously experienced a heart attack. The study was being conducted by Brigham and Women's Hospital.
The DSMB instructed TRACER investigators to discontinue the study drug in subjects and begin close-out activities. For TRA-2P, investigators were told to discontinue the study drug in those who experienced a stroke prior to entering or during the course of the study. They could continue the study drug in those who entered the trial with a history of a previous heart attack or peripheral arterial disease, an estimated 75% of the subjects.
The www.clinicaltrials.gov identifier for the TRACER trial is NCT00527943, and NCT00526474 for TRA-2P. Peter Kim, PhD, President of Merck Research Laboratories, emphasized in a conference call that the goal of vorapaxar was to find "an antiplatelet agent that we could add on top of standard of care." Vorapaxar is one of the company's key programs in Phase III, and it had anticipated filing for approval this year. While financials were not discussed, at an estimated cost of $26,000 per subject in Phase III trials, this represents a $338 million hit to the company's bottom line.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.